{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:36Z","timestamp":1790887776655,"version":"4.1.0"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006378","name":"Universitas Indonesia","doi-asserted-by":"publisher","award":["NKB_292"],"award-info":[{"award-number":["NKB_292"]}],"id":[{"id":"10.13039\/501100006378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis in Indonesia remains a serious public health concern, as the country has the third-largest number of multidrug-resistant tuberculosis (MDR-TB) patients in the world. Bedaquiline and levofloxacin are the primary drug regimen for MDR-TB treatment in Indonesia. This study aimed to investigate whether the Cmax\/MIC of bedaquiline and levofloxacin differs between patients with sputum conversion and those without sputum conversion during the first four months of MDR-TB treatment in Indonesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort study was performed in adult patients (18\u201365 years old) treated with the 18\u201324-month oral regimen. Patients were excluded if they were pregnant or HIV positive, with uncontrolled diabetes, or had any of the following severe conditions: cancer, digestive, cardiovascular system disorders, hepatic, or renal problems. Two blood samples were collected to measure the plasma concentrations of bedaquiline and levofloxacin using liquid chromatography-tandem mass spectrometry (LC-MS\/MS).\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      (Mtb) isolates from patients\u2019 sputum were used to determine the MIC of individual drugs using liquid growth media (MGIT).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 74 patients enrolled, 16 dropped out during the four-month follow-up period. Blood samples were successfully obtained 1\u20132 hours after drug administration from 48 patients and 4\u20136 hours after drug administration from 32 patients, which were used for pharmacokinetic analysis. Sputum conversion was detected in 84.5% of patients during four months of the MDR-TB treatment. The mean Cmax\/MIC ratio of bedaquiline was higher in the sputum conversion group compared with the non-conversion group (9.10 vs. 1.65, respectively). Meanwhile, a small difference in the Cmax\/MIC ratio of levofloxacin was observed between the sputum conversion group and the non-conversion group; it was not significant (45.64 vs. 41.72, respectively; p\u2009=\u20090.941).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cmax\/MIC of bedaquiline was higher in MDR-TB patients with sputum conversion compared to those without conversion within the first four months of treatment, suggesting a potential relationship between Cmax\/MIC of bedaquiline and sputum conversion, which was not seen in the levofloxacin cases. However, the application of clinical practice should be carefully considered and supported by further study in various settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0336210","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:40:26Z","timestamp":1767206426000},"page":"e0336210","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Peak Plasma Concentration (Cmax)\/Minimum Inhibitory Concentration (MIC) of bedaquiline and levofloxacin with special attention to the sputum conversion in the treatment of multidrug-resistant tuberculosis in Indonesia"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1888-0897","authenticated-orcid":true,"given":"Nina","family":"Mariana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anggi","family":"Gayatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indah Suci","family":"Widyahening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-2427","authenticated-orcid":true,"given":"Budiman","family":"Bela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-5619","authenticated-orcid":true,"given":"Soedarsono","family":"Soedarsono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iin","family":"Maemunah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamarlina","family":"Rosamarlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-7909","authenticated-orcid":true,"given":"Vivi","family":"Setiawaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8678","authenticated-orcid":true,"given":"Vithal Prasad","family":"Myneedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erni Juwita","family":"Nelwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purwantyastuti","family":"Ascobat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"pone.0336210.ref001","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024"},{"key":"pone.0336210.ref002","volume-title":"Dashboard Data Kondisi TBC di Indonesia Data Diperbarui 3 Februari 2025","author":"Indonesian Ministry of Health","year":"2025"},{"issue":"4","key":"pone.0336210.ref003","first-page":"430","article-title":"The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline","volume":"55","author":"MF Setyawan","year":"2023","journal-title":"Acta Med Indones"},{"key":"pone.0336210.ref004","doi-asserted-by":"crossref","first-page":"20503121231171350","DOI":"10.1177\/20503121231171350","article-title":"Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda","volume":"11","author":"O Kushemererwa","year":"2023","journal-title":"SAGE Open Med"},{"issue":"1","key":"pone.0336210.ref005","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1186\/s12889-021-11427-y","article-title":"Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients","volume":"21","author":"SEJ van de Berg","year":"2021","journal-title":"BMC Public Health"},{"key":"pone.0336210.ref006","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jgar.2023.03.002","article-title":"Pharmacokinetic\/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation","volume":"33","author":"P Ma","year":"2023","journal-title":"J Glob Antimicrob Resist"},{"key":"pone.0336210.ref007","volume-title":"Pharmacokinetic\/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation","author":"World Health Organization WHO","year":"2021"},{"issue":"4","key":"pone.0336210.ref008","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/2040622315582325","article-title":"Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?","volume":"6","author":"SK Field","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"pone.0336210.ref009","first-page":"78","article-title":"Antimicrobial stewardship from principles","volume-title":"British Society for Antimicrobial Chemotherapy","author":"AL Macgowan","year":"2018"},{"issue":"1","key":"pone.0336210.ref010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3892\/etm.2020.8715","article-title":"Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation","volume":"20","author":"G Cao","year":"2020","journal-title":"Exp Ther Med"},{"key":"pone.0336210.ref011","doi-asserted-by":"crossref","first-page":"860472","DOI":"10.3389\/fvets.2022.860472","article-title":"Pharmacodynamic Parameters of Pharmacokinetic\/Pharmacodynamic (PK\/PD) Integration Models","volume":"9","author":"L Zhang","year":"2022","journal-title":"Front Vet Sci"},{"key":"pone.0336210.ref012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ebiom.2018.01.005","article-title":"Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study","volume":"28","author":"NA Ismail","year":"2018","journal-title":"EBioMedicine"},{"key":"pone.0336210.ref013","volume-title":"Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2018"},{"issue":"4","key":"pone.0336210.ref014","first-page":"1","article-title":"Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients","author":"S Ghimire","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0336210.ref015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fmicb.2020.01182","article-title":"Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India","volume":"11","author":"A Dusthackeer","year":"2020","journal-title":"Front Microbiol"},{"issue":"11","key":"pone.0336210.ref016","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02399-20","article-title":"Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis","volume":"65","author":"P Ngwalero","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0336210.ref017","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40262-024-01363-6","article-title":"Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling","volume":"63","author":"K Mehta","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"pone.0336210.ref018","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/IDR.S153499","article-title":"Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis","volume":"11","author":"L Lv","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"4","key":"pone.0336210.ref019","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01677-19","article-title":"Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study","volume":"58","author":"K Kaniga","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"10","key":"pone.0336210.ref020","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.5588\/ijtld.14.0277","article-title":"Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations","volume":"19","author":"P Kambli","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0336210.ref021","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.jctube.2024.100444","article-title":"Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis","volume":"36","author":"NF Maranchick","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"1","key":"pone.0336210.ref022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","article-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems","volume":"17","author":"A-G M\u00e4rtson","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"pone.0336210.ref023","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.idc.2007.07.004","article-title":"Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations","volume":"21","author":"SJ Bergman","year":"2007","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"pone.0336210.ref024","article-title":"The pharmacodynamic bases of the prescription of antimicrobials","author":"JR Azanza Perea","year":"2019","journal-title":"Rev Esp Quim"},{"key":"pone.0336210.ref025","doi-asserted-by":"crossref","first-page":"1022090","DOI":"10.3389\/fphar.2023.1022090","article-title":"Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients","volume":"14","author":"G Shao","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"pone.0336210.ref026","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/psp4.12147","article-title":"Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin","volume":"5","author":"EM Svensson","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"pone.0336210.ref027","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ajodo.2018.07.005","article-title":"Simple randomization may lead to unequal group sizes. Is that a problem?","volume":"154","author":"WM Shibasaki","year":"2018","journal-title":"Am J Orthod Dentofacial Orthop"},{"issue":"2","key":"pone.0336210.ref028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pathogens10020165","article-title":"The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance","volume":"10","author":"B Kowalska-Krochmal","year":"2021","journal-title":"Pathogens"},{"issue":"2","key":"pone.0336210.ref029","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jvp.12917","article-title":"The pharmacokinetic\/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal","volume":"44","author":"P-L Toutain","year":"2021","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"pone.0336210.ref030","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"E As\u00edn-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"issue":"3","key":"pone.0336210.ref031","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3201\/eid3103.241488","article-title":"High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia","volume":"31","author":"D Zimenkov","year":"2025","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pone.0336210.ref032","doi-asserted-by":"crossref","DOI":"10.1177\/1751143714564816","article-title":"Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient","author":"S Shah","year":"2015","journal-title":"J Intensive Care Soc"},{"issue":"2","key":"pone.0336210.ref033","doi-asserted-by":"crossref","first-page":"1901908","DOI":"10.1183\/13993003.01908-2019","article-title":"Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?","volume":"55","author":"Global Tuberculosis Network Bedaquiline Study Group","year":"2020","journal-title":"Eur Respir J"},{"key":"pone.0336210.ref034","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.2147\/IDR.S374687","article-title":"The Correlations of Minimal Inhibitory Concentration Values of Anti-TB Drugs with Treatment Outcomes and Clinical Profiles in Patients with Multidrug-Resistant Tuberculosis (MDR-TB) in China","volume":"15","author":"Q Tang","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"4","key":"pone.0336210.ref035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cpdd.1517","article-title":"Effect of High-Fat Diets on the Pharmacokinetics of Bedaquiline Fumarate Tablet: A Trial in Healthy Chinese Participants","volume":"14","author":"X Wang","year":"2025","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"pone.0336210.ref036","first-page":"1","article-title":"A study on factors influencing delayed sputum conversion in newly diagnosed pulmonary tuberculosis based on bacteriology and genomics","volume":"2024","author":"M Pang","year":"2024","journal-title":"Sci Rep"},{"key":"pone.0336210.ref037","first-page":"1","article-title":"Sputum culture conversion and its predictors among drug-resistant pulmonary tuberculosis patients in eastern Ethiopia","volume":"0","author":"G Mulugeta","year":"2024","journal-title":"Int Health"},{"issue":"7","key":"pone.0336210.ref038","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/rccm.202407-1354OC","article-title":"Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial","volume":"211","author":"PPJ Phillips","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"pone.0336210.ref039","doi-asserted-by":"crossref","first-page":"2003463","DOI":"10.1183\/13993003.03463-2020","article-title":"Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China","volume":"57","author":"L Davies Forsman","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0336210.ref040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12879-024-09009-5","article-title":"Time to sputum culture conversion and its associated factors among drug-resistant tuberculosis patients: a systematic review and meta-analysis","volume":"24","author":"Y Wenlu","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pone.0336210.ref041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52225\/narra.v4i3.1660","article-title":"Tuberculosis treatment outcomes and associated factors: A retrospective study in West Nusa Tenggara, Indonesia","volume":"4","author":"M Meiyanti","year":"2024","journal-title":"Narra J"},{"key":"pone.0336210.ref042","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2018.11.228","article-title":"The impact of anemia in prolong culture conversion amongs MDR-TB patients in persahabatan hospital Indonesia","volume":"79","author":"SN Irbah","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pone.0336210.ref043","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ijmy.ijmy_24_23","article-title":"Impact of anemia on sputum smear conversion and treatment outcomes among newly diagnosed tuberculosis patients in Southern India","volume":"12","author":"RN Hithaish Kumar","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"pone.0336210.ref044","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/B978-0-12-370607-2.00023-5","article-title":"Disorder of Red Blood Cells: Anemia.","volume-title":"Hematopathology","author":"F. Naeim","year":"2008"},{"issue":"3","key":"pone.0336210.ref045","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/antibiotics8030108","article-title":"Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?","volume":"8","author":"SK Pitman","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"pone.0336210.ref046","first-page":"217","article-title":"Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns","volume":"10","author":"C-H Gao","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"pone.0336210.ref047","first-page":"51","article-title":"Antibiotics and nutritional implications-the drugs-nutrients interactions","volume":"3","author":"Shobha","year":"2019","journal-title":"Acta Sci Nutr Heal"},{"issue":"9","key":"pone.0336210.ref048","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"RPG van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:40:36Z","timestamp":1767206436000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336210"}},"subtitle":[],"editor":[{"given":"Saki","family":"Raheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":48,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336210","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}